<DOC>
	<DOCNO>NCT02266745</DOCNO>
	<brief_summary>This Phase I , open-label , multi-center , non-randomized , dose-escalation study conduct two part : Dose Escalation Phase Dose Confirmation Phase . The Dose Escalation Phase determine Maximum Tolerated Dose ( MTD ) recommend Phase 2 dose ( ) ( RP2D ) PT-112 Injection evaluate safety tolerability , PK ( pharmacokinetic ) preliminary clinical effect . The Dose Confirmation Phase cohort expansion MTD PT-112 Injection . Subjects tolerate drug experience progressive disease may continue receive PT-112 Injection discretion Principal Investigator 6 cycle . For subject tolerate PT-112 Injection experience objective response stable disease 6 cycle , Sponsor continue provide PT-112 Injection separate mechanism , e.g. , extension protocol .</brief_summary>
	<brief_title>A Phase 1 Study PT-112 Injection Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase I , open-label , multi-center , non-randomized , dose-escalation study conduct two part : Dose Escalation Phase Dose Confirmation Phase . The Dose Escalation Phase determine Maximum Tolerated Dose ( MTD ) recommend Phase 2 dose ( ) ( RP2D ) PT-112 Injection evaluate safety tolerability , PK ( pharmacokinetic ) preliminary clinical effect . The Dose Confirmation Phase cohort expansion MTD PT-112 Injection . Subjects tolerate drug experience progressive disease may continue receive PT-112 Injection discretion Principal Investigator 6 cycle . For subject tolerate PT-112 Injection experience objective response stable disease 6 cycle , Sponsor continue provide PT-112 Injection separate mechanism , e.g. , extension protocol .</detailed_description>
	<criteria>Key Pathologically confirm advanced solid tumor standard therapy proven provide clinical benefit exist longer effective . Eastern Collaborative Oncology Group ( ECOG ) Performance Status 01 ( Appendix 1 ) . Evaluable disease , either measurable physical examination image Response Evaluation Criteria Solid Tumors ( RECIST v1.1 , Appendix 2 ) , informative tumor marker ( ) . Laboratory value Screening Visit : 1 . Absolute neutrophil count ( ANC ) ≥1,500/mm3 ; 2 . Platelets ≥100,000/mm3 ; 3 . Total bilirubin ≤1.5 × upper limit normal ( ULN ) ( subject Gilbert 's Syndrome allow direct bilirubin within normal limit ) ; 4 . Aspartate aminotransferase ( AST [ SGOT ] ) ≤2.5 × ULN ; 5 . Alanine aminotransferase ( ALT [ SGPT ] ) ≤2.5 × ULN ; 6 . Serum albumin ≥3.0 gm/dL ; 7 . Serum creatinine ≤1.5 mg/dL measure creatinine clearance ≥60 mL/min ; Negative serum β hCG ( human chorionic gonadotropin ) test woman childbearing potential ( defined woman ≤50 year age , &gt; 50 year age history amenorrhea ≤12 month prior study entry ) . Subjects primary liver cancer hepatic metastasis eligible enroll , provide , Screening Visit , follow criterion meet : 1 . Total bilirubin high ULN ; 2 . AST ALT ≤5 × ULN ; 3 . Severe liver dysfunction ( ChildPugh Class B C ) present ; 4 . Subjects history esophageal bleed varix sclerosed banded bleeding episode occur prior 6 month . If know history brain metastasis , either treat radiation therapy untreated , metastatic disease must stable judgment Principal Investigator must require ongoing treatment corticosteroid anticonvulsant . Willing able provide write Informed Consent comply requirement study . Key Any cytotoxic chemotherapy within 21 day prior initiation study drug . Any immunomodulatory drug therapy , antineoplastic hormonal therapy ( unless dose stable 3 month prior Baseline remain stable trial ) , immunosuppressive therapy , corticosteroid &gt; 20 mg/day prednisone equivalent , growth factor treatment ( e.g. , erythropoietin ) within 14 day prior initiation study drug . Presence acute chronic toxicity prior chemotherapy , exception alopecia , resolve ≤Grade 1 , determine National Cancer Institute Common Toxicity Criteria Adverse Effects ( CTCAE ) v 4.0 ( http : //evs.nci.nih.gov/ftp1/CTCAE/About.html ) . Receipt 3 prior regimen cytotoxic chemotherapy metastatic disease unless prior approval grant Sponsor . Bone marrow reserve , clinical judgment Principal Investigator , adequate participation trial . Radiotherapy within 28 day prior baseline . Receipt radiotherapy &gt; 25 % bone marrow . Major surgery within 28 day prior initiation study drug . Life expectancy &lt; 12 week . Active bacterial , viral , fungal infection require systemic therapy . Known human immunodeficiency virus acquire immunodeficiency syndrome related illness . Clinically significant hearing impairment , judge Principal Investigator . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . Unstable cardiac dysrhythmias persistent prolongation correct QT interval ( QTc ) ( Fridericia ) &gt; 450 msec male &gt; 470 msec female . Previous malignancy , except nonsquamouscell carcinoma skin carcinoma insitu uterine cervix , unless tumor treat curative intent 2 year prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>